Phase III Study of Hypofractionated, Dose Escalation Radiation Therapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)
In North America, the number of new cases of prostate cancer increases every year. Many
efforts have been made to develop more efficient and safer curative treatments for high risk
prostate cancer patients.
This phase III clinical trial is designed to compare the safety of a standard pelvic
external beam radiation therapy (EBRT) combined with a high dose rate brachytherapy (HDRB)
boost (direct insertion of radiation source over a period of minutes via flexible needles
temporarily inserted in the prostate) to a shorter course of hypofractionated dose
escalation radiation therapy (larger radiation dose per daily treatment) in patients with high
risk prostate cancer.
The investigators plan to recruit 296 patients across Quebec who will be randomized in
either treatment plan.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society